Cargando…
Single-cell analysis of multiple myelomas refines the molecular features of bortezomib treatment responsiveness
Both the tumor and tumor microenvironment (TME) are crucial for pathogenesis and chemotherapy resistance in multiple myeloma (MM). Bortezomib, commonly used for MM treatment, works on both MM and TME cells, but innate and acquired resistance easily develop. By single-cell RNA sequencing (scRNA-seq),...
Autores principales: | Jung, Seung-Hyun, Park, Sung-Soo, Lim, Ji-Young, Sohn, Seon Yong, Kim, Na Yung, Kim, Dokyeong, Lee, Sug Hyung, Chung, Yeun-Jun, Min, Chang-Ki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723182/ https://www.ncbi.nlm.nih.gov/pubmed/36380017 http://dx.doi.org/10.1038/s12276-022-00884-z |
Ejemplares similares
-
A Case of Drug-Induced Hepatitis due to Bortezomib in Multiple Myeloma
por: Kim, Youngwoon, et al.
Publicado: (2012) -
A Pilot Study of Bortezomib in Korean Patients with Relapsed or Refractory Myeloma
por: Lee, Keun-Wook, et al.
Publicado: (2005) -
Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study
por: Jung, Jongheon, et al.
Publicado: (2023) -
Combination treatment with 2-methoxyestradiol overcomes bortezomib resistance of multiple myeloma cells
por: Song, In-Sung, et al.
Publicado: (2013) -
Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)